Living Cell Technologies’ Accepts Proposed Revised Conditions for Diabetes Clinical Trial in New Zealand
News Jun 23, 2009
Living Cell Technologies Limited has announced the Company has accepted a preliminary decision from the New Zealand Minister of Health, the Honorable Tony Ryall, to issue a new conditional authorization for its New Zealand Phase I/IIa clinical trial of DIABECELL® for insulin dependent diabetes.
The Minister’s letter states that “the proposed condition that would require (LCT) to amend the inclusion criteria of (LCT’s) study to limit participation in the study to patients with brittle diabetes who suffer from significant metabolic instability is essential to ensure that the study complies with international guidelines, which require that participants obtain maximum benefit possible from their participation in the study”.
“The other proposed changes to the existing conditions are matters that LCT has agreed are appropriate during the peer review process, or are changes of a procedural, rather than a substantive nature ….”
The Company said that the clinical protocol for the New Zealand diabetes trial has already been amended according to the proposed new conditions from the Minister. LCT is pleased to have worked with the Ministry of Health to finalize the protocols for the clinical trial of DIABECELL®.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018